Orca Bio Inc. is bringing to market a precision-engineered cell therapy approach designed to improve outcomes in patients with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) following U.S. FDA approval of Tregzi, a first-of-its-kind, personalized cell therapy. Read More
The data mill continues to churn out encouraging results in pancreatic ductal adenocarcinoma (PDAC), with shares of Ramat Gan, Israel-based Can-Fite Biopharma Ltd. benefiting from the latest, phase IIa dispatch that pushed shares (NYSE:CANF) up 58%, or $1.73, to close July 1 at $4.70. Read More
Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics AG and its phase III-ready drug potravitug, a treatment for BK virus-associated infections and nephropathy in immune-compromised kidney transplant patients. Read More
As China becomes a major source of global clinical trial evidence, the retraction of a high-profile China-led lung cancer study is raising questions about whether journals, regulators and drug developers have adequate systems to validate fast-moving clinical claims. Read More
The House Select Committee on China launched an investigation into clinical trials involving U.S. companies that are conducted at Chinese military hospitals and in Xinjiang, China. Read More
Nearly 60% of venture capital financing rounds in the first half (H1) of 2026 were over $100 million, with the volume of those deals topping $7.5 billion, up 23% from the year-ago semester and just slightly below H1 2024, which saw a total of $7.84 billion in large financings. Read More
Zimmer Biomet Holdings Inc.’s deal to buy Pacira Biosciences Inc.’s Iovera system for up to $140 million and Eurobio Scientific SA’s acquisition of Caredx Inc.’s lab products business for $171.2 million are symptomatic of a broader trend among med-tech and diagnostics companies using targeted acquisitions to strengthen specific areas of their portfolio. Read More
Regardless of whether the Republicans or Democrats come out on top in November’s midterm congressional elections, some of the state primaries in the U.S. have already guaranteed major shuffles in key House and Senate committees overseeing national health issues. Read More
Total med-tech financing through the first half of 2026 reached $12.28 billion, landing between 2024’s $13.94 billion and 2023’s $10.75 billion over the same period and trailing 2025’s $17.56 billion. The figure reflects a sector that is holding well above the low years of 2022 and 2023. Read More
Alebund Pharmaceuticals (Jiangsu) Ltd. was the third Chinese biotech company to debut in Hong Kong this month, with June IPO proceeds from Alebund, Longbio Pharma Co. Ltd. and Shaanxi Micot Pharmaceutical Technology Co. Ltd. totaling about HK$4.7 billion (US$600 million). Read More
New hires and promotions in the biopharma and med-tech industries, including: ALX, Dariohealth, Depuy, Dogwood, Exicure, Exonate, Flare, Kinaset, LB, Muna, Opzira, Palvella, Quince, R1, Xeris. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Abivax, Abbvie, AC Immune, Ascendis, Beone, Catalyst, Cogent, Genelux, Genmab, Moleculin, Pasithea, Sanofi, Skyhawk, Vistagen, Vivos. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Candela, Cerenome, Eli Lilly, Innovent, Kyowa, Orion, Pacira, Plus, Shilpa, Zimmer. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Arcutis, Aurenar, Biomerieux, Cogent, Envoy, Hengrui, Monopar, Novaliq, Novocure, Praxis, Roche, Saluda, Sarepta, Starmed, Unicycive. Read More
